Factors Influencing the Occurrence of Grades II Through IV Acute GVHD
| . | No. of Evaluable Patients . | No. (%) of Affected Patients . | Cumulative Probability4-150 . | P-Value4-151 . |
|---|---|---|---|---|
| Study population | 60 | 18 (30%) | 48% ± 10% | |
| HLA-identical sibling donors | 36 | 7 (19%) | 29% ± 10% | <.05 |
| Alternative family donors | 24 | 11 (46%) | 47% ± 15% | |
| GVH-matched donors | 41 | 7 (17%) | 25% ± 9% | <.003 |
| GVH-mismatched donors | 19 | 11 (58%) | 86% ± 12% | |
| HVG-matched donors | 37 | 7 (19%) | 28% ± 10% | <.03 |
| HVG-mismatched donors | 23 | 11 (48%) | 75% ± 14% | |
| F → F | 10 | 2 (20%) | 33% ± 21% | NS |
| M → M | 19 | 5 (26%) | 52% ± 21% | |
| M → F | 11 | 1 (9%) | 9% ± 9% | |
| F → M | 20 | 10 (50%) | 70% ± 15% | |
| CSP ± Prednisolone | 8 | 3 (37%) | 57% ± 22% | NS |
| sMTX + CSP | 52 | 15 (29%) | 48% ± 11% | |
| No G-CSF after PBSCT | 16 | 8 (50%) | 84% ± 14% | <.03 |
| G-CSF after PBSCT | 44 | 10 (23%) | 32% ± 10% | |
| Early disease stage | 31 | 8 (25%) | 41% ± 13% | NS |
| Advanced disease stage | 29 | 10 (36%) | 56% ± 14% | |
| Donor age | ||||
| <30 | ||||
| 30-39 | ||||
| 40-49 | ||||
| ≥50 | 11 | 5 (45%) | 78% ± 19% | NS |
| 13 | 2 (15%) | 17% ± 11% | ||
| 14 | 4 (29%) | 55% ± 21% | ||
| 22 | 7 (32%) | 37% ± 11% | ||
| Patient age | ||||
| <30 | ||||
| 30-39 | ||||
| 40-49 | ||||
| ≥50 | 12 | 5 (42%) | 76% ± 20% | NS |
| 21 | 8 (32%) | 56% ± 16% | ||
| 16 | 2 (12%) | 13% ± 9% | ||
| 11 | 3 (27%) | 64% ± 27% |
| . | No. of Evaluable Patients . | No. (%) of Affected Patients . | Cumulative Probability4-150 . | P-Value4-151 . |
|---|---|---|---|---|
| Study population | 60 | 18 (30%) | 48% ± 10% | |
| HLA-identical sibling donors | 36 | 7 (19%) | 29% ± 10% | <.05 |
| Alternative family donors | 24 | 11 (46%) | 47% ± 15% | |
| GVH-matched donors | 41 | 7 (17%) | 25% ± 9% | <.003 |
| GVH-mismatched donors | 19 | 11 (58%) | 86% ± 12% | |
| HVG-matched donors | 37 | 7 (19%) | 28% ± 10% | <.03 |
| HVG-mismatched donors | 23 | 11 (48%) | 75% ± 14% | |
| F → F | 10 | 2 (20%) | 33% ± 21% | NS |
| M → M | 19 | 5 (26%) | 52% ± 21% | |
| M → F | 11 | 1 (9%) | 9% ± 9% | |
| F → M | 20 | 10 (50%) | 70% ± 15% | |
| CSP ± Prednisolone | 8 | 3 (37%) | 57% ± 22% | NS |
| sMTX + CSP | 52 | 15 (29%) | 48% ± 11% | |
| No G-CSF after PBSCT | 16 | 8 (50%) | 84% ± 14% | <.03 |
| G-CSF after PBSCT | 44 | 10 (23%) | 32% ± 10% | |
| Early disease stage | 31 | 8 (25%) | 41% ± 13% | NS |
| Advanced disease stage | 29 | 10 (36%) | 56% ± 14% | |
| Donor age | ||||
| <30 | ||||
| 30-39 | ||||
| 40-49 | ||||
| ≥50 | 11 | 5 (45%) | 78% ± 19% | NS |
| 13 | 2 (15%) | 17% ± 11% | ||
| 14 | 4 (29%) | 55% ± 21% | ||
| 22 | 7 (32%) | 37% ± 11% | ||
| Patient age | ||||
| <30 | ||||
| 30-39 | ||||
| 40-49 | ||||
| ≥50 | 12 | 5 (42%) | 76% ± 20% | NS |
| 21 | 8 (32%) | 56% ± 16% | ||
| 16 | 2 (12%) | 13% ± 9% | ||
| 11 | 3 (27%) | 64% ± 27% |
Abbreviations: GVHD, graft versus host disease; HLA, human leukocyte antigen; GVH, graft versus host; HVG, host versus graft; CSP, ciclosporin; sMTX, short course of methotrexate; G-CSF, granulocyte colony-stimulating factor; PBSCT, peripheral blood stem cell transplantation; NS, not significant.
Kaplan-Meier product limit estimates.
Significances by log-rank statistics.